Abstract: Monoclonal antibodies and antigen binding fragments that specifically bind pneumococcal proteins, specifically pneumococcal histidine triad protein (PhtD) and pneumococcal surface protein A (PspA), are provided. Also disclosed are nucleic acid molecules encoding the antibody, antigen binding fragment, a VH or VL of the antibody, or a multipiece antibody including the VH and/or VL, vectors including these nucleic acid molecules, and host cells transfected with these vectors. Methods of inhibiting, treating, and detecting a Streptococcus pneumoniae infection are also provided.

Abstract: Provided herein is a protein, referred to as a Pn3Pase protein, that degrades the capsular polysaccharide of serotype 3 Streptococcus pneumoniae. The disclosure includes a genetically modified cell that includes a Pn3Pase protein, and compositions that include the protein, the polynucleotide encoding the protein, the genetically modified cell, or a combination thereof. Also provided are methods for using a Pn3Pase protein, including methods for contacting a S. pneumoniae having a type III capsular polysaccharide with a Pn3Pase protein, increasing deposition of at least one complement component on the surface of a S. pneumoniae, treating an infection in a subject, treating a symptom in a subject, decreasing colonization of a subject by S. pneumoniae, or a combination thereof.

Abstract: The present disclosure includes catalytically active truncations of a protein, referred to as a PnSPase protein, that degrade the capsular polysaccharide of serotype 3 Streptococcus pneumoniae. The disclosure includes a genetically modified cell that includes a PnSPase protein of the present disclosure, and compositions that include the protein, the polynucleotide encoding the protein, the genetically modified cell, or a combination thereof. Also provided are methods for using a PnSPase protein of the present disclosure, including methods for contacting a S. pneumoniae having a type III capsular polysaccharide with a PnSPase protein, increasing deposition of at least one complement component on the surface of a S. pneumoniae, treating an infection in a subject, treating a symptom in a subject, decreasing colonization of a subject by S. pneumoniae, or a combination thereof.

Abstract: The present disclosure provides peptides derived from CRM197 and Tetanus toxoid that can be used to generate an immune response in an individual. The present disclosure includes isolated peptides and multimers of isolated peptides. Also provided are compositions that include the isolated peptide or the multimer.

Abstract: Provided herein is a protein, referred to as a Pn3Pase protein, that degrades the capsular polysaccharide of serotype 3 Streptococcus pneumoniae. The disclosure includes a genetically modified cell that includes a Pn3Pase protein, and compositions that include the protein, the polynucleotide encoding the protein, the genetically modified cell, or a combination thereof. Also provided are methods for using a Pn3Pase protein, including methods for contacting a S. pneumoniae having a type III capsular polysaccharide with a Pn3Pase protein, increasing deposition of at least one complement component on the surface of a S. pneumoniae, treating an infection in a subject, treating a symptom in a subject, decreasing colonization of a subject by S. pneumoniae, or a combination thereof.

Abstract: The present disclosure provides isolated polynucleotides encoding a mature Mycobacterium tuberculosis protein selected from Ag85A, Ag85B, and Ag85C, where the protein does not include a signal for glycosylation, such as a N-glycosylation consensus sequon. Also disclosed are M. tuberculosis proteins selected from Ag85A, Ag85B, and Ag85C that do not include a signal for glycosylation, such as a N-glycosylation consensus sequon, and/or are not glycosylated, and methods for using the polynucleotides and proteins.

Abstract: Provided herein is a protein, referred to as a Pn3Pase protein, that degrades the capsular polysaccharide of serotype 3 Streptococcus pneumoniae. The disclosure includes a genetically modified cell that includes a Pn3Pase protein, and compositions that include the protein, the polynucleotide encoding the protein, the genetically modified cell, or a combination thereof. Also provided are methods for using a Pn3Pase protein, including methods for contacting a S. pneumoniae having a type III capsular polysaccharide with a Pn3Pase protein, increasing deposition of at least one complement component on the surface of a S. pneumoniae, treating an infection in a subject, treating a symptom in a subject, decreasing colonization of a subject by S. pneumoniae, or a combination thereof.

Abstract: Heparin is synthesized from a polysaccharide comprised of a 1-4 glycosidically linked alternating polymer of uronic acid and glucosamine residues, wherein the uronic acid is selected from iduronic and glucuronic acid, wherein the glucosamine is partially N-sulfated; by a series of selective reactions catalyzed by recombinant enzymes.

Abstract: Heparosan is sulfated at the iduronic acid residue by providing a reaction mixture comprising C5 epimerase to convert glucuronic acid to iduronic acid, and at least one O-sulfotransferase (OST) enzyme and 3?-phosphoadenosine 5?-phosphosulfate (PAPS).

Abstract: A method of sulfating a polysaccharide is provided. The method can include providing a reaction mixture comprising at least one O-sulfotransferase (OST) enzyme and 3?-phosphoadenosine 5?-phosphosulfate (PAPS); incubating a polysaccharide substrate with the reaction mixture, wherein production of the sulfated polysaccharide from the polysaccharide substrate is catalyzed by the OST enzyme with a conversion of the PAPS to adenosine 3?,5?-diphosphate (PAP); and providing a reaction condition which modifies PAP to reduce an inhibitory effect of PAP on the polysaccharide sulfation.